Index Entries

Niel A. Karrow, Umesh K. Shandilya, Steven Pelech, Lauraine Wagter-Lesperance, Deanna McLeod, Byram Bridle, and Bonnie A. Mallard
November 18, 2021
Vaccines
University of Guelph (Canada)

"Abstract: Vaccines have been developed under accelerated timelines to combat the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus. Although they are considered the best approach for preventing mortality, when assessing the safety of these vaccines, pregnant women have not been included in clinical trials. Thus, vaccine safety for this demographic, as well as for the developing fetus and neonate, remains to be determined. A global effort has been underway to encourage pregnant women to get vaccinated despite the uncertain risk posed to them and their offspring. Given this, post-hoc data collection, potentially for years, will be required to determine the outcomes of COVID-19 and vaccination on the next generation... In this review, we have explored components of the first-generation viral vector and mRNA COVID-19 vaccines that are believed to contribute to adverse reactions and which may negatively impact fetal and neonatal development."

1. Introduction: There is a concerted global effort underway to encourage pregnant women to get vaccinated despite the lack of safety data for this demographic, the rationale being that pregnant women who get COVID-19 are more likely to get critically ill and have adverse fetal/neonatal outcomes. However, this rationale is not supported by all studies, and vaccination without long-term safety data from a randomized clinical trial and close medical oversight does not follow a precautionary principle, which is the standard of care in this group...

2. Lipid Nanoparticles (LNPs) in the COVID-19 mRNA Vaccines...

3. Viral Vector COVID-19 Vaccines...

4. Bioactivity of the SARS-CoV-2 Spike Protein...

5. The SARS-CoV-2 Spike Protein Triggers Autoimmune Responses"

document
adverse events,COVID-19,lipid nanoparticles,reproductive system issues,SARS-CoV-2 spike protein,vaccines